Abbott (NYSE:ABT) today announced results from real-world studies demonstrating benefits with its FreeStyle Libre continuous glucose monitoring (CGM) technology. Results from the REFLECT studies show that Libre CGM is associated with a significant … [Read More...] about Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
Main Content
Sponsored Content
Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Manufacturing automation is crucial to achieving the precision, quality, and volume required in the medical device industry. Advanced robotics, AI, modular designs, and wireless technology offer the … [Read More...] about Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Featured Posts
Senseonics opens $50M public offering, $25M private placement with Abbott
Senseonics (NYSE:SENS) announced today that it commenced an underwritten public offering of common stock worth $50 million. The long-term implantable continuous glucose monitor (CGM) maker expects to grant underwriters a 30-day option to purchase … [Read More...] about Senseonics opens $50M public offering, $25M private placement with Abbott
Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
Abbott (NYSE:ABT) today announced results from real-world studies demonstrating benefits with its FreeStyle Libre continuous glucose monitoring (CGM) technology. Results from the REFLECT studies show that Libre CGM is associated with a significant … [Read More...] about Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
BD files patent infringement lawsuit against Baxter over infusion pump tech
BD (NYSE:BDX) filed a lawsuit in a U.S. District Court alleging patent infringement by Baxter (NYSE:BAX) related to infusion pump technology. The company filed its complaint in the U.S. District Court for the District of Delaware on May 12, … [Read More...] about BD files patent infringement lawsuit against Baxter over infusion pump tech
Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
Tandem Diabetes Care (Nasdaq:TNDM) shared in an SEC filing that its Capillary Biomedical (CapBio) subsidiary won FDA 510(k) clearance for a new infusion set. The company won clearance for its SteadiSet Infusion Set, according to an SEC Form 8-K. … [Read More...] about Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
Dexcom promotes Jake Leach to president role
Dexcom (Nasdaq:DXCM) announced today that it promoted Jake Leach to the role of president, in addition to his post as COO. Leach originally took over as COO in 2022. He previously served as chief technology officer (CTO), starting in 2018. In that … [Read More...] about Dexcom promotes Jake Leach to president role
Roche invests $550M to make Indianapolis a CGM manufacturing hub
Roche announced today that it plans to invest up to $550 million to expand its continuous glucose monitoring (CGM) site in the U.S. The company plans to invest in its Diagnostics site in Indianapolis in a project that runs through 2030. It expects … [Read More...] about Roche invests $550M to make Indianapolis a CGM manufacturing hub
Embecta to undergo further restructuring, lowers guidance amid tariff impact
Embecta (Nasdaq:EMBC) stock was down today after news of restructuring and mixed second-quarter results. Shares of EMBC were down more than 8% to $12.12 apiece near the close of trading today. While the company continues to work through the … [Read More...] about Embecta to undergo further restructuring, lowers guidance amid tariff impact
Insulet stock rises on Street-beating Q1, 29% sales uptick
Insulet's (Nasdaq:PODD) stock soared more than 20% today on first-quarter results that exceeded the consensus forecast. Shares of PODD were trading at around $307 a share near the close of trading, the day after the company's evening earnings … [Read More...] about Insulet stock rises on Street-beating Q1, 29% sales uptick
Senseonics posts Q2 sales beat, submits 365-day CGM for CE mark
Senseonics (NYSE:SENS) shares dipped after hours today on first-quarter results that beat revenue projections on Wall Street. Shares of SENS fell 5% to 70¢ apiece in post-market trading today. The Germantown, Maryland-based long-term implantable … [Read More...] about Senseonics posts Q2 sales beat, submits 365-day CGM for CE mark
Astronauts to use diabetes tech in outer space on upcoming mission
A mission to outer space includes plans to utilize modern diabetes management technology to assess its viability in microgravity. The Ax-4 mission, set to launch on May 29, aims to demonstrate that astronauts with insulin-dependent diabetes can be … [Read More...] about Astronauts to use diabetes tech in outer space on upcoming mission
In case you missed it
- Beta Bionics posts Q1 sales beat, raises 2025 guidance
- Dexcom expands Oura partnership with Stelo integration
- IDE Group launches ophthalmic auto-injector
- Medtronic Diabetes adds former Moderna exec as chief marketing officer
- Analysts are high on Dexcom after Q1 results, $750M repurchase program
- Tandem stock rises after hours on Q1 sales beat
- Insulet earns insulin patch pump patent victory against EOFlow with permanent injunction
- Orchestra BioMed wins FDA IDE for sirolimus-angioballoon
- Abbott integrates Libre CGM data into Epic EHR workflows
- Sequel Med Tech, Senseonics to integrate year-long CGM into automated insulin delivery system
- Ashley McEvoy named president and CEO at Insulet
- Cordis shares positive study results from multiple drug-eluting balloon studies
- Medtronic submits interoperable insulin pump to FDA to advance collaboration with Abbott
- Data backs Boston Scientific drug-eluting stent
- Biolinq closes $100M Series C funding round for biosensor platform
Clinical Trials
Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
Abbott (NYSE:ABT) today announced results from real-world studies demonstrating benefits with its FreeStyle Libre continuous glucose monitoring (CGM) technology. Results from the REFLECT studies show that Libre CGM is associated with a significant reduction in the risk of hospitalization for heart complications in people with diabetes. Data demonstrated that CGM can help lessen the severity […]
Glucotrack can proceed with long-term glucose monitor study in Australia
Glucotrack (Nasdaq:GCTK) announced today that it received a hospital’s ethical approval to study its continuous blood glucose monitor (CBGM). The St. Vincent’s Hospital Melbourne Human Research Ethics Committee (HREC) gave the nod for a long-term clinical study. It plans to include participants with both type 1 and type 2 diabetes using the CBGM. Rutherford, New […]
Cordis shares positive study results from multiple drug-eluting balloon studies
Cordis announced new data from two major peripheral studies evaluating its Selution SLR drug-eluting balloon. The Miami Lakes, Florida-based company presented 12-month results from the SUCCESS PTA study at the Charing Cross Symposium in London. It then shared SELUTION SFA Japan three-year results today at the Japan Endovascular Treatment Conference in Osaka. According to Cordis, the studies […]
Data backs Boston Scientific drug-eluting stent
Boston Scientific today shared study data supporting the use of its Eluvia drug-eluting stent for treating PAD. The company shared multiple new clinical data sets at Charing Cross 2025 in London today. Findings reinforced the growing body of evidence supporting the Eluvia stent for treating peripheral artery disease (PAD) — particularly in the superficial femoral […]
R3 Vascular reports first patient treated in next-gen drug-eluting scaffold study
R3 Vascular announced today that a doctor treated the first patient in the ELITE-BTK pivotal trial of its drug-eluting bioresorbable scaffold. Dr. Brian DeRubertis of New York-Presbyterian and Weill Cornell Medicine treated the first patient. The trial evaluates the company’s next-generation Magnitude drug-eluting bioresorbable scaffold for below-the-knee peripheral arterial disease (PAD). Mountain View, California-based R3 […]
